Huminsulin Normal Für Pen (Insulin Human (Rdna))

Huminsulin Normal Für Pen is indicated for the management of blood glucose in adults and children with diabetes.

• Treatment of type 1 diabetes mellitus when endogenous insulin production is insufficient.
• Adjunct therapy for type 2 diabetes mellitus inadequately controlled with oral agents.
• Mealtime (prandial) insulin to cover carbohydrate intake and correct post‑prandial hyperglycaemia.
• Basal insulin support in basal‑bolus regimens for flexible glucose control.
• Use in hospitalized patients requiring rapid insulin titration under medical supervision.

• Insulin human is a recombinant analogue of endogenous human insulin that binds with high affinity to the insulin receptor on the surface of muscle, adipose and hepatic cells. Receptor activation triggers intrinsic tyrosine‑kinase activity, leading to phosphorylation of insulin‑receptor substrates and downstream signaling through the PI3‑kinase/Akt pathway. This cascade promotes translocation of GLUT‑4 transporters, enhances glucose uptake, stimulates glycogen synthesis and suppresses hepatic gluconeogenesis, thereby lowering plasma glucose levels.

Adverse reactions to Huminsulin Normal Für Pen are generally related to its pharmacologic action and formulation.

Common

• Mild to moderate hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Localized pain, redness, swelling or bruising at the injection site.
• Lipohypertrophy or lipoatrophy at repeated injection sites.
• Transient weight gain associated with improved glycaemic control.
• Itching or urticaria without systemic involvement.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms requiring assistance.
• Anaphylactic or anaphylactoid reactions, including airway swelling and hypotension.
• Significant hypokalemia secondary to intracellular shift of potassium.
• Generalized edema or fluid retention, particularly in patients with cardiac or renal disease.
• Development of high‑titer insulin antibodies that diminish therapeutic effect.

When prescribing or using Huminsulin Normal Für Pen, several precautionary measures should be considered to ensure safe and effective therapy.

• Regular self‑monitoring of blood glucose is essential to detect hypo‑or hyperglycaemia and guide dose adjustments.
• Dose reductions may be required during acute illness, reduced food intake, or increased physical activity.
• Severe renal or hepatic impairment may prolong insulin action; monitor closely.
• Pregnancy and lactation safety should be assessed by a clinician; benefits usually outweigh risks.
• Store the pen at controlled room temperature, protected from light, and discard after the in‑use period.
• Do not use the product in individuals with known hypersensitivity to human insulin or any excipients.

Huminsulin Normal Für Pen can interact with several medicines that alter glucose metabolism or insulin action.

Avoid

• Simultaneous administration of additional rapid‑acting insulin preparations, which can precipitate profound hypoglycaemia.
• Combination with sulfonylureas or meglitinides without dose adjustment, increasing the risk of low blood glucose.

Use with caution

• Corticosteroids, which raise blood glucose and may require higher insulin doses.
• Beta‑blockers, which can mask hypoglycaemia symptoms and delay recovery.
• Thiazide diuretics or ACE inhibitors, which may affect electrolyte balance and insulin sensitivity.
• Alcohol intake can cause unpredictable glucose changes and increase hypoglycaemia risk.
• Hormonal therapies such as oral contraceptives or HRT may modify insulin sensitivity and require monitoring.